The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach ...

The researchers found that administering 75 grams of vitamin C three times a week doubled overall survival rates of patients ...

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...

The Center for Metastasis Research eXcellence (MET-X) is an interdisciplinary and collaborative program at Fred Hutchinson Cancer Center focused on one of the most challenging areas of cancer biology: ...

The FDA advised that the on-going VIRAGE Phase 2b study should not be expanded into a Phase 3 study; rather, the optimal path forward for the VCN-01 PDAC program is to conduct a stand-alone Phase 3 ...

the sudden rise in pancreatic cancer incidence is largely being driven by another type of tumor — endocrine cancers. They tend to be indolent, taking years or even decades to grow and spread ...